For example, although CHOP and R-CHOP had both been commonly adopted in NHL clinical treatments, some studies suggested that R-CHOP could significantly reduce the risk of treatment failure [11] and improve OS among patients [12] while another study implied that rituximab did not improve clinical outcomes [13]. Here, DDIT3 is linked to non-Hodgkin lymphoma.